Ozen pick's parent Relative failed to treat Parkinson's disease in the exam.

The idea was very appetizing. GLP-1-class drugs, including WEGOVY and OZEMPIC, have proved miraculous in weight loss and treatment of other diseases. Some researchers also wanted the drug to help treat some of the most difficult illnesses. This is a brain disease like Parkinson's disease.

But now, at least in the case of Parkinson's disease, its hope seems to be dark. A random study of randomly assigned Parkinson's disease patients to take Excnida, the parent Relative of Ozen pick, never had the profit or deceleration of the progress of the degenerative disease 96 weeks later.

There were no sub -groups that affected the patient's symptoms, affected brain scanning, or profits. No matter how researchers sliced ​​data, the results were the same.

This study, which was published on Tuesday on Tuesday, is a bad news for 500,000 Americans diagnosed with Parkinson's disease. Symptoms include trembling, rigidity and balance. Patients can also develop dementia. Treatment containing drugs and deep brain irritation is useful for symptoms. However, there is no treatment to delay the progress of the disease.

“It's very disappointing,” said Dr. Thomas Faltinie of the University of London. “We were hoping to pass through and get positive results.”

Parkinson's experts shared his emotions.

“This is a calm moment,” said Dr. Michael S. Okun, an expert in Parkinson's disease at the University of Florida and a national medical advisor of the Parkinson Sonson Foundation. “This is a really well -made study, and it came out empty -handed.”

This discovery could affect researchers who are asking for a new GLP-1 drug to slow down the Alzheimer's disease course or whether it can prevent illness.

New research involved 194 Parkinson's disease treated at six research hospitals in the UK. The patient is injected once a week for 96 weeks of Exenatide, a type 2 diabetes made by Astra Seneca, and is sold under the brand name Byetta. Or in placebo. The trial was funded by the British National Health Therapy Research Institute and supported subtrosadies from Charity Cure Parkinsons and Van Andel Research Institute.

This drug is in the same class as Ozen Pick and Wegovi, and reduces blood sugar levels. Everything is a so-called GLP-1 receptor agonist called GLP-1. Excnatide is not as powerful to withdraw as new drugs, but experts have no reason to believe that recent drugs work different in brain disease research.

According to researchers, the results are especially unfortunate because the GLP-1 drug could help Parkinson's disease patients.

The GLP-1 drug protected neurons from the damage to the laboratory research, and was protected by rats that were given brain injury due to Parkinson's disease.

The results began to seem to apply to patients.

“People have begun to dig a claim database,” explained that researchers have examined a large database that shows the drugs taken by people. Researchers asked if the patients who took the GLP-1 would be less likely to get Parkinson's disease, or if they would have a more progressing illness.

The result was promising.

They saw epidemiological research. They found that diabetes who took GLP-1 is unlikely to have Parkinson's disease.

Later, two small studies suggested that Excnatide could slow the progress of Parkinson's disease for one year.

Following the progress hints of progress last year at New England Journal of Medicine, it is a larger but more preliminary research, a glp -1, which has not been on the market, that is, the progress of the disease is slightly slower. I found out that it seemed to be. year.

At that time, Dr. Okun stated that the result was “biting the end of the disease modification.”

“Last year we had a one -year trial and a small signal,” said David Standard, a researcher of Parkinson's disease at Alabama University in Birmingham. “What happens if you get longer? Well, this is long, not much here.”

The problem of studying Parkinson's disease GLP-1 is that it is not clear that Excnidid should be in the brain.

“I won't do this kind of research unless you learn what a target is,” said Dr. Stand Art. “What is the biochemical you are trying to change in your brain? How does these medicines work?”